GlaxoSmithKline plc: Great For Investors, Great For The World

As well as a recent news item being good news for shareholders in GlaxoSmithKline plc (LON: GSK), it is also positive for the rest of the world, too.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

As every Fool knows, investing is all about making money. The raison d’etre for buying shares is to one day sell them at a higher price than you paid, as well as receiving dividends between those two dates.

Indeed, the business world is focused on profit, and rightly so. However, I’ve always been of the opinion that the function of business within a capitalist society such as ours is not only to make people rich, but to improve the lives of our fellow citizens.

This leads me neatly onto the healthcare sector and, more importantly, onto GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US). It has recently been given a boost after one of its subsidiaries, ViiV Healthcare, received regulatory approval for an HIV treatment.

The US Food and Drug Administration (FDA) gave authorisation for the subsidiary to commercialise ‘dolutegravir’, which belongs to a class of drugs called integrase inhibitors.

The treatment, which will be branded as Tivicay, has the potential to eventually become a backbone for treatment for millions of HIV patients worldwide as part of a ‘first line’ drug cocktail.

Indeed, it has the potential to revolutionise treatment and could compete with existing HIV drugs.

The subsidiary is 76% owned by GlaxoSmithKline and the approval of Tivicay is the first successfully developed drug by ViiV, which has been in operation for around 4 years.

The regulatory approval should give a substantial financial boost to GlaxoSmithKline, meaning it is great news for investors in the shares. Of course, it is also fantastic news for the millions of people worldwide who are seeking more effective treatment for HIV. For me, this is capitalism at its best: creating wealth and improving the status quo in one form or another.

Of course, this is not the only positive piece of news flow surrounding new drug developments for GlaxoSmithKline this year. It continues to receive positive news flow surrounding FDA approvals, and the company has an impressive pipeline of drugs as well.

Furthermore, it trades on a price-to-earnings (P/E) ratio of 14.8, which compares favourably to the healthcare industry group, which has a P/E of 17.7, and to the FTSE 100, which has a P/E of 15.2.

In addition, a yield of 4.4% beats the FTSE 100 yield of 3.5% and currently offers a return above and beyond inflation.

Indeed, if (like me) you are concerned about low interest rates and the possible effect of inflation, I would recommend you read this exclusive report entitled The Motley Fool’s Top Income Share For 2013.

It’s completely free to take a look and it may just provide your portfolio with the income it needs to offset somewhat the effects of inflation. Click here to take a look.

> Peter owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

Potentially 42% undervalued, is this FTSE 100 company a sleeping giant?

The FTSE 100 is full of opportunities for the patient investor, and I think I may have found one that…

Read more »

Investing Articles

AstraZeneca, a mega-cap growth stock that just got cheaper!

Our writer takes a closer look at this growth stock -- which also happens to be the largest company of…

Read more »

Investing Articles

How I’d invest £5,000 in FTSE growth stocks right now

Sumayya Mansoor explains why she’s bullish about these FTSE growth stocks, and would be willing to buy some shares.

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

ITV shares down after revenue guidance cut in first-half interim results

After releasing results this morning, the ITV share price slumped. But with several metrics looking positive, how will this effect…

Read more »

Investing Articles

This FTSE 100 stock’s down 50%, and a director just bought 8,000 shares

Directors of this blue-chip company have been snapping up a load of its shares. Should I do likewise and buy…

Read more »

Investing Articles

The BT share price is far too cheap, analysts say!

The BT share price fell on Thursday 25 July after the company's Q1 results. Dr James Fox takes a closer…

Read more »

Investing Articles

Is this the start of a stock market crash?

Global stock markets are experiencing some turbulence at the moment. Could investors be looking at a major decline in share…

Read more »

Investing Articles

As the Anglo American share price holds up on H1 results, should I buy?

Failed takeover attempts and major restructuring all affect the Anglo American share price. Here's what's happening at H1 time.

Read more »